1INTRODUCTIONLung cancer has been the most commonly diagnosed cancer in the world for several decades. World Health Organization estimated that 1.8 million new lung cancer cases would occur in 2012 (12.9% of all cancer), in the latest GLOBOCAN 2012. The disease remains as the highest prevalent cancer among men globally (1.2 million), with generally lower incidence rates among women. Lung cancer is the most common cause of death for cancer worldwide accounting for nearly, one‐fifth of cancer deaths (1.59 million deaths, 19.4% of the total deaths), with an increasing trend between 2002 and 2008 statistics: 1.4 million deaths (18% of the total) in 2008 and 1.18 million deaths (17.6% of the total) in 2002.Previous research confirmed that lung cancer risk is increasing in the general population including non‐smokers because of factors other than tobacco smoking, which has been traditionally recognized as the most important carcinogenic factor. The proportion of never‐smoking patients with non‐small cell lung cancer (NSCLC) has been increasing over time: 15.9% in the 1970s, 25.8% in the 1980s, 30.4% in the 1990s and 32.8% in the 2000s. Furthermore, the never‐smoking NSCLC group also had higher incidence of adenocarcinoma (87.8%) in comparison to the smoking NSCLC group (49.1%)
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera